编者按
MARIPOSA研究已证实,埃万妥单抗联合拉泽替尼可为表皮生长因子受体(EGFR)突变晚期非小细胞肺癌(NSCLC)患者的一线治疗带来显著的总生存期(OS)获益。然而,该双靶方案伴随的皮肤不良事件(AEs)常发生于治疗早期,如何进一步优化毒性管理以保障患者的持续用药与生活质量,是临床关注的焦点。
在2026年欧洲肿瘤内科学会(ESMO)大会上,由韩国延世癌症中心胸部肿瘤内科Byoung Chul Cho教授团队开展的COCOON研究最新队列数据重磅公布。该研究旨在探索简化皮肤预防方案联合皮下注射(SC)埃万妥单抗+拉泽替尼的临床价值,以期通过更灵活、便捷的给药模式提升患者的长期治疗获益。会议期间,《肿瘤瞭望》特邀Byoung Chul Cho教授接受专访,解读COCOON研究数据,并梳理本届年会中肺癌领域备受关注的三大研究方向。
《肿瘤瞭望》
基于COCOON研究的最新数据,您如何评价SC剂型联合主动皮肤管理方案对患者治疗依从性和生活质量的影响?
Byoung Chul Cho教授:表皮生长因子受体(EGFR)突变是非小细胞肺癌(NSCLC)最常见的驱动基因亚型之一。MARIPOSA Ⅲ期研究证实,EGFR/MET双特异性抗体埃万妥单抗联合第三代EGFR酪氨酸激酶抑制剂(EGFR-TKI)兰泽替尼相较奥希替尼,一线治疗EGFR突变晚期NSCLC患者可显著改善其总生存期(OS),但治疗相关皮肤不良反应发生率较高,是限制患者治疗耐受性与依从性的关键问题。
COCOON研究正是针对这一临床痛点开展,核心目标为探索有效干预策略,降低该治疗方案中≥2级皮肤不良反应的发生率。该研究既往结果已显示,规范化皮肤管理方案相较常规护理可显著减少中重度目标皮肤不良事件,本次会议进一步公布了皮下制剂(SC)队列的探索结果。
本次研究纳入两个非随机的皮下注射埃万妥单抗队列,所有入组患者均接受简化皮肤预防方案,包括口服四环素类药物联合神经酰胺类保湿剂。两个队列采用差异化给药策略:标准皮下队列在第1周期每周给药1次埃万妥单抗,第2周期起调整为每4周给药1次;兰泽替尼先导队列在第1周期即启动每日兰泽替尼治疗,第2周期起每2周加用埃万妥单抗,第3周期起改为每4周给药1次,两组均在第1周期第1天启动兰泽替尼每日口服治疗。
研究结果显示,简化皮肤预防方案相较常规护理可有效降低皮疹、甲沟炎等中重度目标皮肤不良反应的发生率,其改善幅度与COCOON主研究的规范管理方案相当。具体来看,标准给药队列中≥2级皮肤AEs的发生率为39%(其中3级及以上为3%),而采用兰泽替尼导入的给药模式,将该发生率进一步降至18%(且无3级及以上事件发生),组间对比OR值为0.31(P=0.0264)。从发生部位来看,无论是面部、躯干、头皮还是甲沟炎,导入队列的发生率均呈现出一致的下降趋势。
在患者耐受性和依从性方面,数据同样令人鼓舞。在治疗的前12周内,拉泽替尼导入队列因皮肤AEs导致的剂量中断、减量和停药比例分别仅为0%、3%和0%(标准队列分别为1%、3%和1%)。此外,SC剂型本身还显著降低了输注相关反应(ARR)的发生率(标准队列仅为1%,导入队列为0%),静脉血栓(VTE)和外周水肿的发生率也与既往报道保持一致。
总之,COCOON研究新队列数据表明,简化版皮肤管理方案结合更灵活的用药策略,在数值和统计学上均显著优化了≥2级皮肤AEs的管理,为提升患者的治疗体验、最大化长期生存获益提供了极具价值的临床参考。
上下滑动可查看
ONCOLOGY FRONTIER:Based on the COCOON data, how do you evaluate the impact of the SC formulation combined with proactive dermatologic management on treatment adherence and quality of life?
Prof. Byoung Chul Cho: I would like to briefly introduce our COCOON study that was presented at ESMO this year. The aim of the COCOON study is to reduce the dermatologic AEs in EGFR-mutant lung cancer patients receiving first-line amivantamab plus lazertinib. As demonstrated in the MARIPOSA phase 3 study, first-line amivantamab plus lazertinib significantly improved overall survival compared to osimertinib in treatment-naive EGFR-mutant advanced NSCLC. Despite the effectiveness of this novel regimen, it is associated with dermatologic AEs in these patients.
Therefore, the primary goal of the COCOON study is to reduce grade 2 or higher dermatologic AEs in EGFR-mutant lung cancer patients receiving first-line amivantamab plus lazertinib. Previously, COCOON dermatologic management showed a significant reduction in moderate to severe dermatologic AEs of interest compared to standard care in this patient population.
In this presentation, we evaluated two non-randomized subcutaneous amivantamab cohorts. All patients received a simplified dermatologic prophylaxis, which included oral tetracycline and ceramide-based moisturizers. One is the standard schedule cohort, and the other is the lazertinib lead-in cohort. In the standard schedule cohort, amivantamab was given weekly in cycle 1, and every 4 weeks from cycle 2. In the lazertinib lead-in cohort, amivantamab was added every 2 weeks in cycle 2, and then every 4 weeks from cycle 3. Both subcutaneous amivantamab cohorts started daily lazertinib on cycle 1, day 1.
The main finding of the new COCOON study was that this simplified dermatologic prophylaxis reduced the moderate to severe dermatologic AEs of interest, such as skin rash and paronychia, compared to standard care. A similar rate of reduction was achieved compared to the main COCOON regimen. Interestingly, when we look at the lazertinib lead-in cohort, this cohort showed a substantial reduction in grade 2 or higher dermatologic AEs compared to the standard subcutaneous cohort.
In summary, our new COCOON studies suggest that simplified dermatologic management, along with a more flexible amivantamab initiation utilizing a less intensified and less frequent induction schedule, showed numerically lower incidence of grade 2 or higher dermatologic AEs compared to both the standard subcutaneous cohort and the main COCOON study.
《肿瘤瞭望》
本届ESMO大会上,有哪些研究进展或热点议题是您最为关注的?哪些创新疗法有望改变当前的临床实践?
Byoung Chul Cho教授:在今年的ESMO大会上,多项重磅发现令人瞩目,我主要关注以下三个方向:
个性化癌症疫苗:黑色素瘤领域成果为早期NSCLC治疗提供新思路
本次会议公布的一项黑色素瘤Ⅲ期INTerpath-001研究显示,在完全切除的黑色素瘤患者中,帕博利珠单抗联合个性化癌症疫苗相较帕博利珠单抗单药可显著延长患者无复发生存期。基于这一积极结果,我非常期待该策略能向早期NSCLC领域转化。目前,已有3项针对早期NSCLC的个性化癌症疫苗Ⅲ期临床研究正在开展,黑色素瘤领域的阳性结果有望为早期肺癌术后辅助治疗的免疫联合疫苗策略提供参考,推动早期肺癌系统治疗模式的革新。
ADC联合免疫治疗:一线NSCLC治疗的潜在范式革新
对于程序性死亡配体1(PD-L1)低表达(尤其是PD-L1<1%)的晚期NSCLC人群,现有标准治疗帕博利珠单抗联合含铂双药化疗相较单纯化疗的生存获益有限,是临床中未满足需求突出的人群。本次会议中,中国研究者报告了OptiTROP-Lung06研究,该研究评估了TROP2 抗体偶联药物(ADC)芦康沙妥珠单抗联合帕博利珠单抗对比化疗联合帕博利珠单抗的疗效。结果显示,TROP2靶向ADC联合帕博利珠单抗一线治疗相较标准免疫化疗方案,可为PD-L1阴性NSCLC患者带来显著生存获益。尽管该研究仅纳入中国人群,但其作为首个概念验证性研究,提示ADC有望替代含铂双药化疗成为一线NSCLC联合治疗的核心组成,该结论仍需全球多中心大样本研究进一步验证。
T细胞衔接器维持治疗:广泛期小细胞肺癌的治疗新突破
塔拉妥单抗是一种双特异性T细胞衔接器(BiTE),已在复发难治性小细胞肺癌中被证实可带来总生存获益。本次会议公布的DeLLphi-305研究进一步探索了其在广泛期小细胞肺癌(ES-SCLC)一线维持治疗中的应用价值:在完成4周期化免诱导且未进展的患者中,随机接受塔拉妥单抗联合免疫检查点抑制剂(ICI)或ICI单药治疗。结果显示,塔拉妥单抗联合免疫检查点抑制剂在一线维持阶段带来显著且具有临床意义的生存获益。该研究结果具有变革临床实践的潜力,有望填补广泛期小细胞肺癌维持治疗的有效方案空白。
上下滑动可查看
ONCOLOGY FRONTIER:Please share which research advances or hot topics in the lung cancer and thoracic tumor fields at this ESMO Congress you are most focused on. Which promising innovative therapies have the potential to change current clinical practice?
Prof. Byoung Chul Cho: During ESMO this year, many new findings were presented.
First, an interesting finding is the personalized cancer vaccine. The personalized cancer vaccine in the INTerpath-001 phase 3 study demonstrated that in completely resected melanoma patients, a combination of pembrolizumab plus a cancer vaccine significantly improved relapse-free survival compared to pembrolizumab monotherapy. I hope this finding will be translated into early-stage NSCLC. I think there are three phase 3 studies ongoing in early-stage NSCLC, including the INTerpath study. Hopefully, this melanoma data will be successfully translated into early-stage NSCLC.
Second, we saw data on ADC combination therapy in first-line NSCLC. We know that in the PD-L1 low patient population, particularly the PD-L1 less than 1% population, the current standard of care is the KEYNOTE-189 regimen, pembrolizumab plus platinum doublet. It showed a modest survival benefit compared to chemo alone. This is a population with a huge unmet medical need. During this conference, Chinese investigators reported a TROP2 ADC in combination with pembrolizumab, which showed a significant survival benefit compared to the standard of care, pembrolizumab plus platinum doublet. So, while this is a China-only study, the data is exciting and needs to be confirmed in the global population. But this is the first proof-of-concept suggesting that ADC may replace a platinum doublet in the first-line NSCLC patient population.
Third, the data on T-cell engagers is very interesting. Tarlatamab, a DLL3 T-cell engager, demonstrated an overall survival benefit in refractory relapsed small cell lung cancer. New data also came from the DeLLphi-305 study. This study evaluated tarlatamab in the first-line maintenance setting for extensive-stage small cell lung cancer. Most small cell lung cancer patients received first-line chemo-immunotherapy as standard care. In those patients who did not experience progressive disease after four cycles of induction chemo-immunotherapy, patients were randomized to tarlatamab plus an immune checkpoint inhibitor versus an immune checkpoint inhibitor alone. The data suggests a substantial and clinically meaningful survival benefit with the ICI combination versus ICI alone in the first-line maintenance setting. So, I think this is transformative and practice-changing data, and I hope to have this regimen in the clinic as quickly as possible.
参考文献:
1.Byoung Chul Cho, et al. Improving prevention of moderate to severe dermatologic adverse events in EGFR-mutant advanced NSCLC treated with first-line (1L) subcutaneous (SC) amivantamab + lazertinib: First results from a new COCOON cohort. 2026 ESMO, 2700RO
2.Georgina V. Long, et al. INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL). 2026 ESMO, LBA1
3.Caicun Zhou, et al. Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1-negative advanced non-squamous (nsq) NSCLC: Randomized phase 3 OptiTROP-Lung06 study. 2026 ESMO, LBA66
4.Jacob Sands, et al. Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial. 2026 ESMO, LBA3
(来源:《肿瘤瞭望》编辑部)
声 明
凡署名原创的文章版权属《肿瘤瞭望》所有,欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用,不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议,如果该信息被用于资讯以外的目的,本站及作者不承担相关责任。